Lisata Therapeutics

443 articles about Lisata Therapeutics

• Hitachi Chemical Co., Ltd. Signs Agreement To Purchase From Caladrius Biosciences The Remaining 80.1% Interest In PCT For $75 Million

  3/17/2017

• Hitachi Chemical Co., Ltd. Signs Agreement To Purchase From Caladrius Biosciences The Remaining 80.1% Interest In PCT For $75 Million

  3/17/2017

• Caladrius Biosciences Announces 2016 Fourth Quarter And Full Year Financial Results

  3/17/2017

• Caladrius Biosciences To Host 2016 Fourth Quarter And Full Year Financial Results Conference Call On March 17, 2017 At 8:30 Am Eastern Time

  3/13/2017

• Caladrius Biosciences Awarded $12.2 Million Grant From CIRM In Support Of Phase II Clinical Trial Of CLBS03 To Treat Type 1 Diabetes

  2/24/2017

• Caladrius Biosciences Release: Biotech Announces Addition Of Three Clinical Sites, Including UCSF, For The Ongoing Phase 2 Study Of CLBS03 In T1D

  1/25/2017

• Caladrius Biosciences Updates Status Of Receipt Of Funds For A Portion Of Previously Announced Private Placement

  1/9/2017

• Caladrius Biosciences To Host 2016 Third Quarter Financial Results Conference Call On November 7 At 5:00 PM Eastern Time

  11/3/2016

• Caladrius Biosciences Appoints Gregory R. Brown, MD, To Its Board Of Directors

  10/12/2016

• Caladrius Biosciences To Present At Upcoming October Conferences

  10/4/2016

• Caladrius Biosciences Subsidiary, PCT, Announces Five-Year Strategic Manufacturing Services Agreement With Adaptimmune

  9/19/2016

• Caladrius Biosciences Enters Into Agreements To Raise $25 Million In Common Equity Priced At Market Without Warrants

  9/15/2016

• Caladrius Biosciences To Present At Upcoming September Conferences

  9/8/2016

• Caladrius Biosciences Reports 2016 Second Quarter Financial Results

  8/10/2016

• Caladrius Biosciences To Host 2016 Second Quarter Financial Results Conference Call On August 9 At 5:00 Pm Eastern Time

  8/2/2016

• Caladrius Biosciences Receives FDA Fast Track Designation For CLBS03 To Treat Recent Onset Type 1 Diabetes

  7/28/2016

• Caladrius Biosciences Announces 1-For-10 Reverse Split

  7/27/2016

• Caladrius Biosciences To Present At Upcoming July Conferences

  7/7/2016

• The Alliance for Regenerative Medicine (ARM) Welcomes New Chairman, Bob Preti, Ph.D., President Of PCT And SVP Of Caladrius Biosciences

  6/28/2016

• Caladrius Biosciences Licenses Key Technology and Subleases Irvine Facility to AiVita Biomedical

  5/26/2016